

Title (en)  
CONTROLLED RELEASE FORMULATION COMPRISING GNRH-II ANALOGS FOR THE TREATMENT OF OR PROTECTION AGAINST DISORDERS OF BONE GROWTH

Title (de)  
FORMULIERUNG MIT KONTROLLIERTER FREISETZUNG ENTHALTEND GNRH-II ANALOGA ZUR BEHANDLUNG ODER VORBEUGUNG VON KNOCHENWACHSTUMSKRANKHEITEN

Title (fr)  
FORMULE A LIBERATION PROLONGEE COMPRENANT DES ANALOGUES DE LA GONADOLIBERINE-II POUR LE TRAITEMENT OU LA PREVENTION DE MALADIES DE LA CROISSANCE OSSEUSE

Publication  
**EP 1140133 A1 20011010 (EN)**

Application  
**EP 99958357 A 19991202**

Priority  
• GB 9904045 W 19991202  
• GB 9826662 A 19981203

Abstract (en)  
[origin: WO0032218A1] A pharmaceutical formulation for the controlled release of a therapeutic peptide or a salt thereof, which peptide has the sequence pyroGlu-His-Trp-Ser-Xaa<1>-Gly-Xaa<2>-Xaa<3>-Pro-Gly-NH<sub>2</sub> wherein Xaa<1> is His or Tyr, Xaa<2> is Trp or Leu, and Xaa<3> is Tyr or Arg, provided that when Xaa<1> is Tyr and Xaa<2> is Leu, then Xaa<3> is not Arg, and which formulation further comprises a pharmaceutically acceptable biodegradable polymer. The formulation can be used for treating bone and prostate disorders.

IPC 1-7  
**A61K 38/09**; **A61K 47/34**; **A61P 19/08**; **A61P 35/00**

IPC 8 full level  
**A61K 9/16** (2006.01); **A61K 38/00** (2006.01); **A61K 38/09** (2006.01); **A61K 47/34** (2006.01); **A61K 9/50** (2006.01); **A61P 3/10** (2006.01); **A61P 13/08** (2006.01); **A61P 19/00** (2006.01); **A61P 19/10** (2006.01); **A61P 35/00** (2006.01); **C07K 7/23** (2006.01); **C07K 14/59** (2006.01)

CPC (source: EP KR)  
**A61K 9/0002** (2013.01 - KR); **A61K 9/1647** (2013.01 - EP KR); **A61K 38/09** (2013.01 - EP KR); **A61P 3/10** (2018.01 - EP); **A61P 13/08** (2018.01 - EP); **A61P 19/00** (2018.01 - EP); **A61P 19/08** (2018.01 - EP); **A61P 19/10** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **C07K 7/23** (2013.01 - EP KR)

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**WO 0032218 A1 20000608**; AU 1573200 A 20000619; AU 770676 B2 20040226; BR 9915943 A 20010821; CA 2353798 A1 20000608; CN 1332635 A 20020123; CZ 20011893 A3 20020515; EE 200100293 A 20020815; EP 1140133 A1 20011010; GB 2344287 A 20000607; GB 9826662 D0 19990127; HR P20010421 A2 20020630; HU P0104943 A2 20020629; HU P0104943 A3 20020828; IL 143496 A0 20020421; JP 2002531411 A 20020924; KR 20010089538 A 20011006; MX PA01005543 A 20030714; NO 20012636 D0 20010529; NO 20012636 L 20010712; NZ 511984 A 20021126; PL 348575 A1 20020603; RU 2233170 C2 20040727; SK 7552001 A3 20020205; TR 200102273 T2 20011221; ZA 200104530 B 20020604

DOCDB simple family (application)  
**GB 9904045 W 19991202**; AU 1573200 A 19991202; BR 9915943 A 19991202; CA 2353798 A 19991202; CN 99815183 A 19991202; CZ 20011893 A 19991202; EE P200100293 A 19991202; EP 99958357 A 19991202; GB 9826662 A 19981203; HR P20010421 A 20010601; HU P0104943 A 19991202; IL 14349699 A 19991202; JP 2000584909 A 19991202; KR 20017006883 A 20010601; MX PA01005543 A 19991202; NO 20012636 A 20010529; NZ 51198499 A 19991202; PL 34857599 A 19991202; RU 2001118040 A 19991202; SK 7552001 A 19991202; TR 200102273 T 19991202; ZA 200104530 A 20010601